Trends in Antibiotic Use among Cardiovascular Heart Disease Inpatients at the Jakaya Kikwete Cardiac Institute in Tanzania from 2016 to 2022
Authors:
- Jackob Aron NdayomwamiJNJackob Aron Ndayomwami
- Hamis Abdalla KanikiHKHamis Abdalla Kaniki
- James MwakyomoJMJames Mwakyomo
- Naizihijwa MajaniNMNaizihijwa Majani
- Reuben Kato MutagaywaRMReuben Kato Mutagaywa
- Peter KisengePKPeter Kisenge
- Mohamed JanabiMJMohamed Janabi
- Raphael Zozimus SangedaRaphael Zozimus Sangeda
Preprint
Abstract
Objective: To analyse trends in antibiotic use among cardiovascular inpatients at the Jakaya Kikwete Cardiac Institute (JKCI), Tanzania, from 2016 to 2022, using the World Health Organisation (WHO) Anatomical Therapeutic Chemical/Defined Daily Dose (ATC/DDD) methodology. Design: Retrospective longitudinal study. Setting: Jakaya Kikwete Cardiac Institute, a 150-bed national referral and teaching hospital in Dar es Salaam, Tanzania. Patients: 11,656 cardiovascular inpatients; 6,612 (56.7%) received at least one systemic antibiotic. Methods: Prescription data (250,591 total; 30,885 antibiotic-related) were extracted from the JKCI MedPro dispensing system. Antibiotic use was expressed in Defined Daily Doses per 100 bed-days (DDD/100). Analyses were conducted using Microsoft Excel, SPSS version 26, and time-series forecasting with AutoRegressive Integrated Moving Average (ARIMA) modelling in R. Results: Overall, antibiotic use was 29.88 DDD/100 bed-days. Injections accounted for more than 55% of use. At the ATC Class 4 level, carbapenems (J01DH) dominated (45.6%), followed by third-generation cephalosporins (17.0%) and extended-spectrum penicillins (14.6%). At the molecular level, meropenem contributed 45.6%, with amoxicillin and ceftriaxone also being prominent; the top 11 antibiotics comprised more than 90% of total use (Drug Utilisation 90% [DU90%]). By WHO Access, Watch, Reserve (AWaRe) classification, Reserve agents contributed 46.4% of use, followed by Watch (31.3%) and Access (21.1%). ARIMA (1,1,0) modelling forecasts a continued upward trend through 2026. Conclusions: Antibiotic use among cardiovascular inpatients at JKCI is high, with heavy reliance on broad-spectrum and Reserve agents. Strengthened antimicrobial stewardship measures, such as intravenous-to-oral switch protocols, DU90 audits, and stricter control of Reserve antibiotic prescribing, are urgently needed to mitigate antimicrobial resistance risks.Keywords
This publication has 24 references indexed in Scilit:
- Antibiotic utilization patterns in Tanzania: a retrospective longitudinal study comparing pre- and intra-COVID-19 pandemic era using Tanzania Medicines and Medical Devices Authority dataJAC-Antimicrobial Resistance, 2024
- Global Burden of Cardiovascular Diseases and Risks, 1990-2022JACC, 2023
- Curbing antimicrobial resistance in post‐COVID Africa: Challenges, actions and recommendationsHealth Science Reports, 2022
- Global burden of bacterial antimicrobial resistance in 2019: a systematic analysisThe Lancet, 2022
- Association of Azithromycin Use With Cardiovascular MortalityJAMA Network Open, 2020
- Antimicrobial point prevalence surveys in two Ghanaian hospitals: opportunities for antimicrobial stewardshipJAC-Antimicrobial Resistance, 2020
- Duration and life-stage of antibiotic use and risk of cardiovascular events in womenEuropean Heart Journal, 2019
- Trends and relationship between antimicrobial resistance and antibiotic use in Xinjiang Uyghur Autonomous Region, China: Based on a 3 year surveillance data, 2014–2016Journal of Infection and Public Health, 2018
- Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales dataThe Lancet Infectious Diseases, 2014
- The European Surveillance of Antimicrobial Consumption (ESAC) Point‐Prevalence Survey of Antibacterial Use in 20 European Hospitals in 2006Clinical Infectious Diseases, 2009